Ketamine as a Novel Psychopharmacotherapy for Eating Disorders: Evidence and Future Directions
Abstract
:1. Introduction
2. Use of Ketamine in Eating Disorders
3. Future Perspectives and Directions
4. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Conflicts of Interest
References
- Schmidt, U.; Adan, R.; Boehm, I.; Campbell, I.C.; Dingemans, A.; Ehrlich, S.; Elzakkers, I.; Favaro, A.; Giel, K.; Harrison, A.; et al. Eating Disorders: The Big Issue. Lancet Psychiatry 2016, 3, 313–315. [Google Scholar] [CrossRef]
- Treasure, J.; Duarte, T.A.; Schmidt, U. Eating Disorders. Lancet 2020, 395, 899–911. [Google Scholar] [CrossRef]
- Allen, K.L.; Byrne, S.M.; Oddy, W.H.; Crosby, R.D. DSM–IV–TR and DSM-5 Eating Disorders in Adolescents: Prevalence, Stability, and Psychosocial Correlates in a Population-Based Sample of Male and Female Adolescents. J. Abnorm. Psychol. 2013, 122, 720–732. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sheehan, D.V.; Herman, B.K. The Psychological and Medical Factors Associated With Untreated Binge Eating Disorder. Prim. Care Companion CNS Disord. 2015, 17, 27178. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mehler, P.S.; Brown, C. Anorexia Nervosa—Medical Complications. J. Eat. Disord. 2015, 3, 11. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mehler, P.S.; Rylander, M. Bulimia Nervosa—Medical Complications. J. Eat. Disord. 2015, 3, 12. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Smink, F.R.E.; van Hoeken, D.; Hoek, H.W. Epidemiology of Eating Disorders: Incidence, Prevalence and Mortality Rates. Curr. Psychiatry Rep. 2012, 14, 406–414. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cardi, V.; Tchanturia, K.; Treasure, J. Premorbid and Illness-Related Social Difficulties in Eating Disorders: An Overview of the Literature and Treatment Developments. Curr. Neuropharmacol. 2018, 16, 1122–1130. [Google Scholar] [CrossRef] [PubMed]
- Hay, P.; Mitchison, D.; Collado, A.E.L.; González-Chica, D.A.; Stocks, N.; Touyz, S. Burden and Health-Related Quality of Life of Eating Disorders, Including Avoidant/Restrictive Food Intake Disorder (ARFID), in the Australian Population. J. Eat. Disord. 2017, 5, 21. [Google Scholar] [CrossRef] [PubMed]
- Mitchison, D.; Hay, P.; Slewa-Younan, S.; Mond, J. Time Trends in Population Prevalence of Eating Disorder Behaviors and Their Relationship to Quality of Life. PLoS ONE 2012, 7, e48450. [Google Scholar] [CrossRef] [Green Version]
- Mond, J.; Hay, P.; Rodgers, B.; Owen, C. Quality of Life Impairment in a Community Sample of Women with Eating Disorders. Aust. N. Z. J. Psychiatry 2012, 46, 561–568. [Google Scholar] [CrossRef] [PubMed]
- Ágh, T.; Kovács, G.; Supina, D.; Pawaskar, M.; Herman, B.K.; Vokó, Z.; Sheehan, D.V. A Systematic Review of the Health-Related Quality of Life and Economic Burdens of Anorexia Nervosa, Bulimia Nervosa, and Binge Eating Disorder. Eat. Weight Disord.—Stud. Anorex. Bulim. Obes. 2016, 21, 353–364. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Deloitte Access Economics. The Social and Economic Cost of Eating Disorders in the United States of America: A Report for the Strategic Training Initiative for the Prevention of Eating Disorders and the Academy for Eating Disorders. Available online: https://www.hsph.harvard.edu/striped/report-economic-costs-of-eating-disorders/ (accessed on 1 February 2022).
- Madden, S.; Morris, A.; Zurynski, Y.A.; Kohn, M.; Elliot, E.J. Burden of Eating Disorders in 5–13-Year-Old Children in Australia. Med. J. Aust. 2009, 190, 410–414. [Google Scholar] [CrossRef]
- Hay, P.; Girosi, F.; Mond, J. Prevalence and Sociodemographic Correlates of DSM-5 Eating Disorders in the Australian Population. J. Eat. Disord. 2015, 3, 19. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Galmiche, M.; Déchelotte, P.; Lambert, G.; Tavolacci, M.P. Prevalence of Eating Disorders over the 2000–2018 Period: A Systematic Literature Review. Am. J. Clin. Nutr. 2019, 109, 1402–1413. [Google Scholar] [CrossRef] [PubMed]
- Qian, J.; Wu, Y.; Liu, F.; Zhu, Y.; Jin, H.; Zhang, H.; Wan, Y.; Li, C.; Yu, D. An Update on the Prevalence of Eating Disorders in the General Population: A Systematic Review and Meta-Analysis. Eat. Weight Disord.—Stud. Anorex. Bulim. Obes. 2021. [Google Scholar] [CrossRef]
- Crow, S.J.; Peterson, C.B.; Swanson, S.A.; Raymond, N.C.; Specker, S.; Eckert, E.D.; Mitchell, J.E. Increased Mortality in Bulimia Nervosa and Other Eating Disorders. Am. J. Psychiatry 2009, 166, 1342–1346. [Google Scholar] [CrossRef] [PubMed]
- Arcelus, J.; Mitchell, A.J.; Wales, J.; Nielsen, S. Mortality Rates in Patients With Anorexia Nervosa and Other Eating Disorders: A Meta-Analysis of 36 Studies. Arch. Gen. Psychiatry 2011, 68, 724–731. [Google Scholar] [CrossRef] [Green Version]
- Birmingham, C.L.; Su, J.; Hlynsky, J.A.; Goldner, E.M.; Gao, M. The Mortality Rate from Anorexia Nervosa. Int. J. Eat. Disord. 2005, 38, 143–146. [Google Scholar] [CrossRef] [PubMed]
- Papadopoulos, F.C.; Ekbom, A.; Brandt, L.; Ekselius, L. Excess Mortality, Causes of Death and Prognostic Factors in Anorexia Nervosa. Br. J. Psychiatry 2009, 194, 10–17. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Franko, D.L.; Keshaviah, A.; Eddy, K.T.; Krishna, M.; Davis, M.C.; Keel, P.K.; Herzog, D.B. A Longitudinal Investigation of Mortality in Anorexia Nervosa and Bulimia Nervosa. Am. J. Psychiatry 2013, 170, 917–925. [Google Scholar] [CrossRef] [PubMed]
- King, J.A.; Frank, G.K.W.; Thompson, P.M.; Ehrlich, S. Structural Neuroimaging of Anorexia Nervosa: Future Directions in the Quest for Mechanisms Underlying Dynamic Alterations. Biol. Psychiatry 2018, 83, 224–234. [Google Scholar] [CrossRef] [PubMed]
- Frank, G.K.W.; Shott, M.E.; DeGuzman, M.C. The Neurobiology of Eating Disorders. Child Adolesc. Psychiatr. Clin. N. Am. 2019, 28, 629–640. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Finch, J.E.; Palumbo, I.M.; Tobin, K.E.; Latzman, R.D. Structural Brain Correlates of Eating Pathology Symptom Dimensions: A Systematic Review. Psychiatry Res. Neuroimaging 2021, 317, 111379. [Google Scholar] [CrossRef]
- Frank, G.K.W. Neuroimaging and Eating Disorders. Curr. Opin. Psychiatry 2019, 32, 478–483. [Google Scholar] [CrossRef] [PubMed]
- Castro-Fornieles, J.; de la Serna, E.; Calvo, A.; Pariente, J.; Andrés-Perpiña, S.; Plana, M.T.; Romero, S.; Flamarique, I.; Gárriz, M.; Bargalló, N. Cortical Thickness 20 Years after Diagnosis of Anorexia Nervosa during Adolescence. Eur. Arch. Psychiatry Clin. Neurosci. 2021, 271, 1133–1139. [Google Scholar] [CrossRef] [PubMed]
- Frank, G.K.W.; Favaro, A.; Marsh, R.; Ehrlich, S.; Lawson, E.A. Toward Valid and Reliable Brain Imaging Results in Eating Disorders. Int. J. Eat. Disord. 2018, 51, 250–261. [Google Scholar] [CrossRef] [PubMed]
- Biezonski, D.; Cha, J.; Steinglass, J.; Posner, J. Evidence for Thalamocortical Circuit Abnormalities and Associated Cognitive Dysfunctions in Underweight Individuals with Anorexia Nervosa. Neuropsychopharmacology 2016, 41, 1560–1568. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Boehm, I.; Geisler, D.; King, J.A.; Ritschel, F.; Seidel, M.; Deza Araujo, Y.; Petermann, J.; Lohmeier, H.; Weiss, J.; Walter, M.; et al. Increased Resting State Functional Connectivity in the Fronto-Parietal and Default Mode Network in Anorexia Nervosa. Front. Behav. Neurosci. 2014, 8, 346. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gaudio, S.; Piervincenzi, C.; Beomonte Zobel, B.; Romana Montecchi, F.; Riva, G.; Carducci, F.; Cosimo Quattrocchi, C. Altered Resting State Functional Connectivity of Anterior Cingulate Cortex in Drug Naïve Adolescents at the Earliest Stages of Anorexia Nervosa. Sci. Rep. 2015, 5, 10818. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kullmann, S.; Giel, K.E.; Teufel, M.; Thiel, A.; Zipfel, S.; Preissl, H. Aberrant Network Integrity of the Inferior Frontal Cortex in Women with Anorexia Nervosa. NeuroImage Clin. 2014, 4, 615–622. [Google Scholar] [CrossRef]
- Park, B.; Moon, T.; Park, H. Dynamic Functional Connectivity Analysis Reveals Improved Association between Brain Networks and Eating Behaviors Compared to Static Analysis. Behav. Brain Res. 2018, 337, 114–121. [Google Scholar] [CrossRef] [PubMed]
- Rangaprakash, D.; Bohon, C.; Lawrence, K.E.; Moody, T.; Morfini, F.; Khalsa, S.S.; Strober, M.; Feusner, J.D. Aberrant Dynamic Connectivity for Fear Processing in Anorexia Nervosa and Body Dysmorphic Disorder. Front. Psychiatry 2018, 9, 273. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Stopyra, M.A.; Simon, J.J.; Skunde, M.; Walther, S.; Bendszus, M.; Herzog, W.; Friederich, H.-C. Altered Functional Connectivity in Binge Eating Disorder and Bulimia Nervosa: A Resting-State FMRI Study. Brain Behav. 2019, 9, e01207. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Boehm, I.; Geisler, D.; Tam, F.; King, J.A.; Ritschel, F.; Seidel, M.; Bernardoni, F.; Murr, J.; Goschke, T.; Calhoun, V.D.; et al. Partially Restored Resting-State Functional Connectivity in Women Recovered from Anorexia Nervosa. J. Psychiatry Neurosci. 2016, 41, 377–385. [Google Scholar] [CrossRef] [Green Version]
- Cowdrey, F.A.; Filippini, N.; Park, R.J.; Smith, S.M.; McCabe, C. Increased Resting State Functional Connectivity in the Default Mode Network in Recovered Anorexia Nervosa. Hum. Brain Mapp. 2014, 35, 483–491. [Google Scholar] [CrossRef]
- Domakonda, M.J.; He, X.; Lee, S.; Cyr, M.; Marsh, R. Increased Functional Connectivity Between Ventral Attention and Default Mode Networks in Adolescents with Bulimia Nervosa. J. Am. Acad. Child Adolesc. Psychiatry 2019, 58, 232–241. [Google Scholar] [CrossRef] [PubMed]
- Cha, J.; Ide, J.S.; Bowman, F.D.; Simpson, H.B.; Posner, J.; Steinglass, J.E. Abnormal Reward Circuitry in Anorexia Nervosa: A Longitudinal, Multimodal MRI Study. Hum. Brain Mapp. 2016, 37, 3835–3846. [Google Scholar] [CrossRef] [Green Version]
- Ehrlich, S.; Lord, A.R.; Geisler, D.; Borchardt, V.; Boehm, I.; Seidel, M.; Ritschel, F.; Schulze, A.; King, J.A.; Weidner, K.; et al. Reduced Functional Connectivity in the Thalamo-Insular Subnetwork in Patients with Acute Anorexia Nervosa. Hum. Brain Mapp. 2015, 36, 1772–1781. [Google Scholar] [CrossRef] [PubMed]
- Geisler, D.; Borchardt, V.; Lord, A.R.; Boehm, I.; Ritschel, F.; Zwipp, J.; Clas, S.; King, J.A.; Wolff-Stephan, S.; Roessner, V.; et al. Abnormal Functional Global and Local Brain Connectivity in Female Patients with Anorexia Nervosa. J. Psychiatry Neurosci. 2016, 41, 6–15. [Google Scholar] [CrossRef] [Green Version]
- Haynos, A.F.; Hall, L.M.J.; Lavender, J.M.; Peterson, C.B.; Crow, S.J.; Klimes-Dougan, B.; Cullen, K.R.; Lim, K.O.; Camchong, J. Resting State Functional Connectivity of Networks Associated with Reward and Habit in Anorexia Nervosa. Hum. Brain Mapp. 2019, 40, 652–662. [Google Scholar] [CrossRef] [PubMed]
- Monteleone, A.M.; Castellini, G.; Volpe, U.; Ricca, V.; Lelli, L.; Monteleone, P.; Maj, M. Neuroendocrinology and Brain Imaging of Reward in Eating Disorders: A Possible Key to the Treatment of Anorexia Nervosa and Bulimia Nervosa. Prog. Neuropsychopharmacol. Biol. Psychiatry 2018, 80, 132–142. [Google Scholar] [CrossRef] [PubMed]
- Kim, K.R.; Ku, J.; Lee, J.-H.; Lee, H.; Jung, Y.-C. Functional and Effective Connectivity of Anterior Insula in Anorexia Nervosa and Bulimia Nervosa. Neurosci. Lett. 2012, 521, 152–157. [Google Scholar] [CrossRef]
- Lee, S.; Ran Kim, K.; Ku, J.; Lee, J.-H.; Namkoong, K.; Jung, Y.-C. Resting-State Synchrony between Anterior Cingulate Cortex and Precuneus Relates to Body Shape Concern in Anorexia Nervosa and Bulimia Nervosa. Psychiatry Res. 2014, 221, 43–48. [Google Scholar] [CrossRef] [PubMed]
- McFadden, K.L.; Tregellas, J.R.; Shott, M.E.; Frank, G.K.W. Reduced Salience and Default Mode Network Activity in Women with Anorexia Nervosa. J. Psychiatry Neurosci. JPN 2014, 39, 178–188. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Heine, L.; Soddu, A.; Gómez, F.; Vanhaudenhuyse, A.; Tshibanda, L.; Thonnard, M.; Charland-Verville, V.; Kirsch, M.; Laureys, S.; Demertzi, A. Resting State Networks and Consciousness: Alterations of Multiple Resting State Network Connectivity in Physiological, Pharmacological, and Pathological Consciousness States. Front. Psychol. 2012, 3, 295. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Vocks, S.; Tuschen-Caffier, B.; Pietrowsky, R.; Rustenbach, S.J.; Kersting, A.; Herpertz, S. Meta-Analysis of the Effectiveness of Psychological and Pharmacological Treatments for Binge Eating Disorder. Int. J. Eat. Disord. 2010, 43, 205–217. [Google Scholar] [CrossRef] [PubMed]
- Hilbert, A.; Hoek, H.W.; Schmidt, R. Evidence-Based Clinical Guidelines for Eating Disorders: International Comparison. Curr. Opin. Psychiatry 2017, 30, 423–437. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hay, P.J.; Touyz, S.; Claudino, A.M.; Lujic, S.; Smith, C.A.; Madden, S. Inpatient versus Outpatient Care, Partial Hospitalisation and Waiting List for People with Eating Disorders. Cochrane Database Syst. Rev. 2019, 1, CD010827. [Google Scholar] [CrossRef] [PubMed]
- De Jong, M.; Schoorl, M.; Hoek, H.W. Enhanced Cognitive Behavioural Therapy for Patients with Eating Disorders: A Systematic Review. Curr. Opin. Psychiatry 2018, 31, 436–444. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Svaldi, J.; Schmitz, F.; Baur, J.; Hartmann, A.S.; Legenbauer, T.; Thaler, C.; von Wietersheim, J.; de Zwaan, M.; Tuschen-Caffier, B. Efficacy of Psychotherapies and Pharmacotherapies for Bulimia Nervosa. Psychol. Med. 2019, 49, 898–910. [Google Scholar] [CrossRef]
- Peat, C.M.; Berkman, N.D.; Lohr, K.N.; Brownley, K.A.; Bann, C.M.; Cullen, K.; Quattlebaum, M.J.; Bulik, C.M. Comparative Effectiveness of Treatments for Binge-Eating Disorder: Systematic Review and Network Meta-Analysis. Eur. Eat. Disord. Rev. J. Eat. Disord. Assoc. 2017, 25, 317–328. [Google Scholar] [CrossRef]
- Van den Berg, E.; Houtzager, L.; de Vos, J.; Daemen, I.; Katsaragaki, G.; Karyotaki, E.; Cuijpers, P.; Dekker, J. Meta-Analysis on the Efficacy of Psychological Treatments for Anorexia Nervosa. Eur. Eat. Disord. Rev. J. Eat. Disord. Assoc. 2019, 27, 331–351. [Google Scholar] [CrossRef]
- Zipfel, S.; Wild, B.; Groß, G.; Friederich, H.-C.; Teufel, M.; Schellberg, D.; Giel, K.E.; de Zwaan, M.; Dinkel, A.; Herpertz, S.; et al. Focal Psychodynamic Therapy, Cognitive Behaviour Therapy, and Optimised Treatment as Usual in Outpatients with Anorexia Nervosa (ANTOP Study): Randomised Controlled Trial. Lancet 2014, 383, 127–137. [Google Scholar] [CrossRef]
- Hans-Christoph, F.; Beate, W.; Stephan, Z.; Henning, S.; Wolfgang, H. Anorexia Nervosa—Focal Psychodynamic Psychotherapy: Theoretical Basis and User Manual; Hogrefe Publishing: Göttingen, Germany, 2019; ISBN 978-1-61334-554-2. [Google Scholar]
- McIntosh, V.V.W.; Jordan, J.; Carter, F.A.; Luty, S.E.; McKenzie, J.M.; Bulik, C.M.; Frampton, C.M.A.; Joyce, P.R. Three Psychotherapies for Anorexia Nervosa: A Randomized, Controlled Trial. Am. J. Psychiatry 2005, 162, 741–747. [Google Scholar] [CrossRef] [PubMed]
- Touyz, S.; Le Grange, D.; Lacey, H.; Hay, P.; Smith, R.; Maguire, S.; Bamford, B.; Pike, K.M.; Crosby, R.D. Treating Severe and Enduring Anorexia Nervosa: A Randomized Controlled Trial. Psychol. Med. 2013, 43, 2501–2511. [Google Scholar] [CrossRef] [PubMed]
- Schmidt, U.; Magill, N.; Renwick, B.; Keyes, A.; Kenyon, M.; Dejong, H.; Lose, A.; Broadbent, H.; Loomes, R.; Yasin, H.; et al. The Maudsley Outpatient Study of Treatments for Anorexia Nervosa and Related Conditions (MOSAIC): Comparison of the Maudsley Model of Anorexia Nervosa Treatment for Adults (MANTRA) with Specialist Supportive Clinical Management (SSCM) in Outpatients with Broadly Defined Anorexia Nervosa: A Randomized Controlled Trial. J. Consult. Clin. Psychol. 2015, 83, 796–807. [Google Scholar] [CrossRef]
- Schmidt, U.; Startup, H.; Treasure, J. A Cognitive Interpersonal Therapy Workbook for Treating Anorexia Nervosa: The Maudsley Model; Routledge: London, UK, 2018; ISBN 978-1-315-72848-3. [Google Scholar]
- Agras, W.S.; Lock, J.; Brandt, H.; Bryson, S.W.; Dodge, E.; Halmi, K.A.; Jo, B.; Johnson, C.; Kaye, W.; Wilfley, D.; et al. Comparison of 2 Family Therapies for Adolescent Anorexia Nervosa: A Randomized Parallel Trial. JAMA Psychiatry 2014, 71, 1279–1286. [Google Scholar] [CrossRef] [PubMed]
- Eisler, I.; Simic, M.; Hodsoll, J.; Asen, E.; Berelowitz, M.; Connan, F.; Ellis, G.; Hugo, P.; Schmidt, U.; Treasure, J.; et al. A Pragmatic Randomised Multi-Centre Trial of Multifamily and Single Family Therapy for Adolescent Anorexia Nervosa. BMC Psychiatry 2016, 16, 422. [Google Scholar] [CrossRef] [Green Version]
- Le Grange, D.; Hughes, E.K.; Court, A.; Yeo, M.; Crosby, R.D.; Sawyer, S.M. Randomized Clinical Trial of Parent-Focused Treatment and Family-Based Treatment for Adolescent Anorexia Nervosa. J. Am. Acad. Child Adolesc. Psychiatry 2016, 55, 683–692. [Google Scholar] [CrossRef] [PubMed]
- Hart, S.; Russell, J.; Abraham, S. Nutrition and Dietetic Practice in Eating Disorder Management. J. Hum. Nutr. Diet. Off. J. Br. Diet. Assoc. 2011, 24, 144–153. [Google Scholar] [CrossRef]
- Ozier, A.D.; Henry, B.W.; American Dietetic Association. Position of the American Dietetic Association: Nutrition Intervention in the Treatment of Eating Disorders. J. Am. Diet. Assoc. 2011, 111, 1236–1241. [Google Scholar] [CrossRef]
- McMaster, C.M.; Fong, M.; Franklin, J.; Hart, S. Dietetic Intervention for Adult Outpatients with an Eating Disorder: A Systematic Review and Assessment of Evidence Quality. Nutr. Rev. 2021, 79, 914–930. [Google Scholar] [CrossRef]
- Ayton, A.K.; Azaz, A.; Horrobin, D.F. A Pilot Open Case Series of Ethyl-EPA Supplementation in the Treatment of Anorexia Nervosa. Prostaglandins Leukot. Essent. Fatty Acids 2004, 71, 205–209. [Google Scholar] [CrossRef]
- Satogami, K.; Tseng, P.-T.; Su, K.-P.; Takahashi, S.; Ukai, S.; Li, D.-J.; Chen, T.-Y.; Lin, P.-Y.; Chen, Y.-W.; Matsuoka, Y.J. Relationship between Polyunsaturated Fatty Acid and Eating Disorders: Systematic Review and Meta-Analysis. Prostaglandins Leukot. Essent. Fatty Acids 2019, 142, 11–19. [Google Scholar] [CrossRef]
- Hart, S.; Marnane, C.; McMaster, C.; Thomas, A. Development of the “Recovery from Eating Disorders for Life” Food Guide (REAL Food Guide)—A Food Pyramid for Adults with an Eating Disorder. J. Eat. Disord. 2018, 6, 6. [Google Scholar] [CrossRef] [Green Version]
- Heruc, G.; Hart, S.; Stiles, G.; Fleming, K.; Casey, A.; Sutherland, F.; Jeffrey, S.; Roberton, M.; Hurst, K. ANZAED Practice and Training Standards for Dietitians Providing Eating Disorder Treatment. J. Eat. Disord. 2020, 8, 77. [Google Scholar] [CrossRef]
- McMaster, C.M.; Wade, T.; Franklin, J.; Hart, S. Development of Consensus-Based Guidelines for Outpatient Dietetic Treatment of Eating Disorders: A Delphi Study. Int. J. Eat. Disord. 2020, 53, 1480–1495. [Google Scholar] [CrossRef]
- McMaster, C.M.; Wade, T.; Basten, C.; Franklin, J.; Ross, J.; Hart, S. Rationale and Development of a Manualised Dietetic Intervention for Adults Undergoing Psychological Treatment for an Eating Disorder. Eat. Weight Disord. EWD 2021, 26, 1467–1481. [Google Scholar] [CrossRef]
- Himmerich, H.; Kan, C.; Au, K.; Treasure, J. Pharmacological Treatment of Eating Disorders, Comorbid Mental Health Problems, Malnutrition and Physical Health Consequences. Pharmacol. Ther. 2021, 217, 107667. [Google Scholar] [CrossRef]
- McElroy, S.L.; Guerdjikova, A.I.; Mori, N.; Romo-Nava, F. Progress in Developing Pharmacologic Agents to Treat Bulimia Nervosa. CNS Drugs 2019, 33, 31–46. [Google Scholar] [CrossRef]
- Himmerich, H.; Benkert, O. Medikamente zur Behandlung von Essstörungen und Adipositas. In Kompendium der Psychiatrischen Pharmakotherapie; Benkert, O., Hippius, H., Eds.; Springer: Berlin/Heidelberg, Germany, 2021; pp. 739–758. ISBN 978-3-662-61753-3. [Google Scholar]
- Appolinario, J.C.; Nardi, A.E.; McElroy, S.L. Investigational Drugs for the Treatment of Binge Eating Disorder (BED): An Update. Expert Opin. Investig. Drugs 2019, 28, 1081–1094. [Google Scholar] [CrossRef]
- Dold, M.; Aigner, M.; Klabunde, M.; Treasure, J.; Kasper, S. Second-Generation Antipsychotic Drugs in Anorexia Nervosa: A Meta-Analysis of Randomized Controlled Trials. Psychother. Psychosom. 2015, 84, 110–116. [Google Scholar] [CrossRef]
- Attia, E.; Steinglass, J.E.; Walsh, B.T.; Wang, Y.; Wu, P.; Schreyer, C.; Wildes, J.; Yilmaz, Z.; Guarda, A.S.; Kaplan, A.S.; et al. Olanzapine Versus Placebo in Adult Outpatients With Anorexia Nervosa: A Randomized Clinical Trial. Am. J. Psychiatry 2019, 176, 449–456. [Google Scholar] [CrossRef]
- Frank, G.K.W.; Shott, M.E.; Hagman, J.O.; Schiel, M.A.; DeGuzman, M.C.; Rossi, B. The Partial Dopamine D2 Receptor Agonist Aripiprazole Is Associated with Weight Gain in Adolescent Anorexia Nervosa. Int. J. Eat. Disord. 2017, 50, 447–450. [Google Scholar] [CrossRef]
- Mitchell, J.E.; Peterson, C.B. Anorexia Nervosa. N. Engl. J. Med. 2020, 382, 1343–1351. [Google Scholar] [CrossRef]
- Blanchet, C.; Guillaume, S.; Bat-Pitault, F.; Carles, M.-E.; Clarke, J.; Dodin, V.; Duriez, P.; Gerardin, P.; Hanachi-Guidoum, M.; Iceta, S.; et al. Medication in AN: A Multidisciplinary Overview of Meta-Analyses and Systematic Reviews. J. Clin. Med. 2019, 8, 278. [Google Scholar] [CrossRef] [Green Version]
- van Hoeken, D.; Hoek, H.W. Review of the Burden of Eating Disorders: Mortality, Disability, Costs, Quality of Life, and Family Burden. Curr. Opin. Psychiatry 2020, 33, 521–527. [Google Scholar] [CrossRef]
- Fichter, M.M.; Quadflieg, N.; Crosby, R.D.; Koch, S. Long-Term Outcome of Anorexia Nervosa: Results from a Large Clinical Longitudinal Study. Int. J. Eat. Disord. 2017, 50, 1018–1030. [Google Scholar] [CrossRef]
- Quadflieg, N.; Fichter, M.M. Long-Term Outcome of Inpatients with Bulimia Nervosa-Results from the Christina Barz Study. Int. J. Eat. Disord. 2019, 52, 834–845. [Google Scholar] [CrossRef]
- Fichter, M.M.; Quadflieg, N.; Hedlund, S. Long-Term Course of Binge Eating Disorder and Bulimia Nervosa: Relevance for Nosology and Diagnostic Criteria. Int. J. Eat. Disord. 2008, 41, 577–586. [Google Scholar] [CrossRef]
- Steinhausen, H.-C. The Outcome of Anorexia Nervosa in the 20th Century. Am. J. Psychiatry 2002, 159, 1284–1293. [Google Scholar] [CrossRef]
- Steinhausen, H.-C.; Weber, S. The Outcome of Bulimia Nervosa: Findings from One-Quarter Century of Research. Am. J. Psychiatry 2009, 166, 1331–1341. [Google Scholar] [CrossRef]
- Eddy, K.T.; Tabri, N.; Thomas, J.J.; Murray, H.B.; Keshaviah, A.; Hastings, E.; Edkins, K.; Krishna, M.; Herzog, D.B.; Keel, P.K.; et al. Recovery From Anorexia Nervosa and Bulimia Nervosa at 22-Year Follow-Up. J. Clin. Psychiatry 2017, 78, 184–189. [Google Scholar] [CrossRef]
- Robinson, P. Severe and Enduring Eating Disorder (SEED): Management of Complex Presentations of Anorexia and Bulimia Nervosa. Wiley. Available online: https://www.wiley.com/en-us/Severe+and+Enduring+Eating+Disorder+%28SEED%29%3A+Management+of+Complex+Presentations+of+Anorexia+and+Bulimia+Nervosa-p-9780470062074 (accessed on 1 February 2022).
- Treasure, J.; Stein, D.; Maguire, S. Has the Time Come for a Staging Model to Map the Course of Eating Disorders from High Risk to Severe Enduring Illness? An Examination of the Evidence. Early Interv. Psychiatry 2015, 9, 173–184. [Google Scholar] [CrossRef]
- Kotilahti, E.; West, M.; Isomaa, R.; Karhunen, L.; Rocks, T.; Ruusunen, A. Treatment Interventions for Severe and Enduring Eating Disorders: Systematic Review. Int. J. Eat. Disord. 2020, 53, 1280–1302. [Google Scholar] [CrossRef]
- Hay, P.; Chinn, D.; Forbes, D.; Madden, S.; Newton, R.; Sugenor, L.; Touyz, S.; Ward, W.; Royal Australian and New Zealand College of Psychiatrists. Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines for the Treatment of Eating Disorders. Aust. N. Z. J. Psychiatry 2014, 48, 977–1008. [Google Scholar] [CrossRef]
- Wonderlich, S.; Mitchell, J.E.; Crosby, R.D.; Myers, T.C.; Kadlec, K.; Lahaise, K.; Swan-Kremeier, L.; Dokken, J.; Lange, M.; Dinkel, J.; et al. Minimizing and Treating Chronicity in the Eating Disorders: A Clinical Overview. Int. J. Eat. Disord. 2012, 45, 467–475. [Google Scholar] [CrossRef]
- Strober, M.; Johnson, C. The Need for Complex Ideas in Anorexia Nervosa: Why Biology, Environment, and Psyche All Matter, Why Therapists Make Mistakes, and Why Clinical Benchmarks Are Needed for Managing Weight Correction. Int. J. Eat. Disord. 2012, 45, 155–178. [Google Scholar] [CrossRef]
- Westmoreland, P.; Mehler, P.S. Caring for Patients With Severe and Enduring Eating Disorders (SEED): Certification, Harm Reduction, Palliative Care, and the Question of Futility. J. Psychiatr. Pract. 2016, 22, 313–320. [Google Scholar] [CrossRef]
- Strand, M.; Sjöstrand, M.; Lindblad, A. A Palliative Care Approach in Psychiatry: Clinical Implications. BMC Med. Ethics 2020, 21, 29. [Google Scholar] [CrossRef] [Green Version]
- Erskine, H.E.; Whiteford, H.A.; Pike, K.M. The Global Burden of Eating Disorders. Curr. Opin. Psychiatry 2016, 29, 346–353. [Google Scholar] [CrossRef]
- Domino, E.F.; Chodoff, P.; Corssen, G. Pharmacologic effects of CI-581, a new dissociative anesthetic, in man. Clin. Pharmacol. Ther. 1965, 6, 279–291. [Google Scholar] [CrossRef] [Green Version]
- Dundee, J.W.; Knox, J.W.; Black, G.W.; Moore, J.; Pandit, S.K.; Bovill, J.; Clarke, R.S.; Love, S.H.; Elliott, J.; Coppel, D.L. Ketamine as an Induction Agent in Anaesthetics. Lancet 1970, 1, 1370–1371. [Google Scholar] [CrossRef]
- Domino, E.F.; Warner, D.S. Taming the Ketamine Tiger. Anesthesiology 2010, 113, 678–684. [Google Scholar] [CrossRef] [Green Version]
- Adams, J.D.; Castagnoli, N.; Trevor, A.J. Quantitative Analysis of Ketamine Enantiomers. Proc. West. Pharmacol. Soc. 1978, 21, 471–472. [Google Scholar]
- Jelen, L.A.; Young, A.H.; Stone, J.M. Ketamine: A Tale of Two Enantiomers. J. Psychopharmacol. 2021, 35, 109–123. [Google Scholar] [CrossRef]
- Ebert, B.; Mikkelsen, S.; Thorkildsen, C.; Borgbjerg, F.M. Norketamine, the Main Metabolite of Ketamine, Is a Non-Competitive NMDA Receptor Antagonist in the Rat Cortex and Spinal Cord. Eur. J. Pharmacol. 1997, 333, 99–104. [Google Scholar] [CrossRef]
- White, P.F.; Ham, J.; Way, W.L.; Trevor, A.J. Pharmacology of Ketamine Isomers in Surgical Patients. Anesthesiology 1980, 52, 231–239. [Google Scholar] [CrossRef]
- White, P.F.; Schüttler, J.; Shafer, A.; Stanski, D.R.; Horai, Y.; Trevor, A.J. Comparative Pharmacology of the Ketamine Isomers. Studies in Volunteers. Br. J. Anaesth. 1985, 57, 197–203. [Google Scholar] [CrossRef]
- Mion, G.; Villevieille, T. Ketamine Pharmacology: An Update (Pharmacodynamics and Molecular Aspects, Recent Findings). CNS Neurosci. Ther. 2013, 19, 370–380. [Google Scholar] [CrossRef]
- Lener, M.S.; Niciu, M.J.; Ballard, E.D.; Park, M.; Park, L.T.; Nugent, A.C.; Zarate, C.A. Glutamate and Gamma-Aminobutyric Acid Systems in the Pathophysiology of Major Depression and Antidepressant Response to Ketamine. Biol. Psychiatry 2017, 81, 886–897. [Google Scholar] [CrossRef] [Green Version]
- Berman, R.M.; Cappiello, A.; Anand, A.; Oren, D.A.; Heninger, G.R.; Charney, D.S.; Krystal, J.H. Antidepressant Effects of Ketamine in Depressed Patients. Biol. Psychiatry 2000, 47, 351–354. [Google Scholar] [CrossRef]
- Matveychuk, D.; Thomas, R.K.; Swainson, J.; Khullar, A.; MacKay, M.-A.; Baker, G.B.; Dursun, S.M. Ketamine as an Antidepressant: Overview of Its Mechanisms of Action and Potential Predictive Biomarkers. Ther. Adv. Psychopharmacol. 2020, 10, 2045125320916657. [Google Scholar] [CrossRef]
- Zarate, C.A.; Singh, J.B.; Carlson, P.J.; Brutsche, N.E.; Ameli, R.; Luckenbaugh, D.A.; Charney, D.S.; Manji, H.K. A Randomized Trial of an N-Methyl-D-Aspartate Antagonist in Treatment-Resistant Major Depression. Arch. Gen. Psychiatry 2006, 63, 856–864. [Google Scholar] [CrossRef]
- Diazgranados, N.; Ibrahim, L.; Brutsche, N.E.; Newberg, A.; Kronstein, P.; Khalife, S.; Kammerer, W.A.; Quezado, Z.; Luckenbaugh, D.A.; Salvadore, G.; et al. A Randomized Add-on Trial of an N-Methyl-D-Aspartate Antagonist in Treatment-Resistant Bipolar Depression. Arch. Gen. Psychiatry 2010, 67, 793–802. [Google Scholar] [CrossRef]
- Zarate, C.A.; Brutsche, N.E.; Ibrahim, L.; Franco-Chaves, J.; Diazgranados, N.; Cravchik, A.; Selter, J.; Marquardt, C.A.; Liberty, V.; Luckenbaugh, D.A. Replication of Ketamine’s Antidepressant Efficacy in Bipolar Depression: A Randomized Controlled Add-on Trial. Biol. Psychiatry 2012, 71, 939–946. [Google Scholar] [CrossRef] [Green Version]
- Ionescu, D.F.; Luckenbaugh, D.A.; Niciu, M.J.; Richards, E.M.; Zarate, C.A. A Single Infusion of Ketamine Improves Depression Scores in Patients with Anxious Bipolar Depression. Bipolar Disord. 2015, 17, 438–443. [Google Scholar] [CrossRef] [Green Version]
- Hu, Y.-D.; Xiang, Y.-T.; Fang, J.-X.; Zu, S.; Sha, S.; Shi, H.; Ungvari, G.S.; Correll, C.U.; Chiu, H.F.K.; Xue, Y.; et al. Single i.v. Ketamine Augmentation of Newly Initiated Escitalopram for Major Depression: Results from a Randomized, Placebo-Controlled 4-Week Study. Psychol. Med. 2016, 46, 623–635. [Google Scholar] [CrossRef]
- Marcantoni, W.S.; Akoumba, B.S.; Wassef, M.; Mayrand, J.; Lai, H.; Richard-Devantoy, S.; Beauchamp, S. A Systematic Review and Meta-Analysis of the Efficacy of Intravenous Ketamine Infusion for Treatment Resistant Depression: January 2009–January 2019. J. Affect. Disord. 2020, 277, 831–841. [Google Scholar] [CrossRef]
- Kryst, J.; Kawalec, P.; Mitoraj, A.M.; Pilc, A.; Lasoń, W.; Brzostek, T. Efficacy of Single and Repeated Administration of Ketamine in Unipolar and Bipolar Depression: A Meta-Analysis of Randomized Clinical Trials. Pharmacol. Rep. PR 2020, 72, 543–562. [Google Scholar] [CrossRef] [PubMed]
- Xiong, J.; Lipsitz, O.; Chen-Li, D.; Rosenblat, J.D.; Rodrigues, N.B.; Carvalho, I.; Lui, L.M.W.; Gill, H.; Narsi, F.; Mansur, R.B.; et al. The Acute Antisuicidal Effects of Single-Dose Intravenous Ketamine and Intranasal Esketamine in Individuals with Major Depression and Bipolar Disorders: A Systematic Review and Meta-Analysis. J. Psychiatr. Res. 2021, 134, 57–68. [Google Scholar] [CrossRef] [PubMed]
- Conley, A.A.; Norwood, A.E.Q.; Hatvany, T.C.; Griffith, J.D.; Barber, K.E. Efficacy of Ketamine for Major Depressive Episodes at 2, 4, and 6-Weeks Post-Treatment: A Meta-Analysis. Psychopharmacology 2021, 238, 1737–1752. [Google Scholar] [CrossRef] [PubMed]
- Li, D.-J.; Wang, F.-C.; Chu, C.-S.; Chen, T.-Y.; Tang, C.-H.; Yang, W.-C.; Chow, P.C.-K.; Wu, C.-K.; Tseng, P.-T.; Lin, P.-Y. Significant Treatment Effect of Add-on Ketamine Anesthesia in Electroconvulsive Therapy in Depressive Patients: A Meta-Analysis. Eur. Neuropsychopharmacol. J. Eur. Coll. Neuropsychopharmacol. 2017, 27, 29–41. [Google Scholar] [CrossRef]
- Ren, L.; Deng, J.; Min, S.; Peng, L.; Chen, Q. Ketamine in Electroconvulsive Therapy for Depressive Disorder: A Systematic Review and Meta-Analysis. J. Psychiatr. Res. 2018, 104, 144–156. [Google Scholar] [CrossRef] [PubMed]
- Zanos, P.; Gould, T.D. Mechanisms of Ketamine Action as an Antidepressant. Mol. Psychiatry 2018, 23, 801–811. [Google Scholar] [CrossRef] [PubMed]
- Zheng, W.; Li, X.-H.; Zhu, X.-M.; Cai, D.-B.; Yang, X.-H.; Ungvari, G.S.; Ng, C.H.; Ning, Y.-P.; Hu, Y.-D.; He, S.-H.; et al. Adjunctive Ketamine and Electroconvulsive Therapy for Major Depressive Disorder: A Meta-Analysis of Randomized Controlled Trials. J. Affect. Disord. 2019, 250, 123–131. [Google Scholar] [CrossRef]
- Basso, L.; Bönke, L.; Aust, S.; Gärtner, M.; Heuser-Collier, I.; Otte, C.; Wingenfeld, K.; Bajbouj, M.; Grimm, S. Antidepressant and Neurocognitive Effects of Serial Ketamine Administration versus ECT in Depressed Patients. J. Psychiatr. Res. 2020, 123, 1–8. [Google Scholar] [CrossRef]
- Kheirabadi, G.; Vafaie, M.; Kheirabadi, D.; Mirlouhi, Z.; Hajiannasab, R. Comparative Effect of Intravenous Ketamine and Electroconvulsive Therapy in Major Depression: A Randomized Controlled Trial. Adv. Biomed. Res. 2019, 8, 25. [Google Scholar] [CrossRef] [PubMed]
- Veraart, J.K.E.; Smith-Apeldoorn, S.Y.; Spaans, H.-P.; Kamphuis, J.; Schoevers, R.A. Is Ketamine an Appropriate Alternative to ECT for Patients with Treatment Resistant Depression? A Systematic Review. J. Affect. Disord. 2021, 281, 82–89. [Google Scholar] [CrossRef] [PubMed]
- Daly, E.J.; Trivedi, M.H.; Janik, A.; Li, H.; Zhang, Y.; Li, X.; Lane, R.; Lim, P.; Duca, A.R.; Hough, D.; et al. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA Psychiatry 2019, 76, 893–903. [Google Scholar] [CrossRef]
- Fedgchin, M.; Trivedi, M.; Daly, E.J.; Melkote, R.; Lane, R.; Lim, P.; Vitagliano, D.; Blier, P.; Fava, M.; Liebowitz, M.; et al. Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1). Int. J. Neuropsychopharmacol. 2019, 22, 616–630. [Google Scholar] [CrossRef] [PubMed]
- Peyrovian, B.; McIntyre, R.S.; Phan, L.; Lui, L.M.W.; Gill, H.; Majeed, A.; Chen-Li, D.; Nasri, F.; Rosenblat, J.D. Registered Clinical Trials Investigating Ketamine for Psychiatric Disorders. J. Psychiatr. Res. 2020, 127, 1–12. [Google Scholar] [CrossRef] [PubMed]
- Siegel, A.N.; Meshkat, S.; Benitah, K.; Lipsitz, O.; Gill, H.; Lui, L.M.W.; Teopiz, K.M.; McIntyre, R.S.; Rosenblat, J.D. Registered Clinical Studies Investigating Psychedelic Drugs for Psychiatric Disorders. J. Psychiatr. Res. 2021, 139, 71–81. [Google Scholar] [CrossRef] [PubMed]
- Martinotti, G.; Chiappini, S.; Pettorruso, M.; Mosca, A.; Miuli, A.; Di Carlo, F.; D’Andrea, G.; Collevecchio, R.; Di Muzio, I.; Sensi, S.L.; et al. Therapeutic Potentials of Ketamine and Esketamine in Obsessive-Compulsive Disorder (OCD), Substance Use Disorders (SUD) and Eating Disorders (ED): A Review of the Current Literature. Brain Sci. 2021, 11, 856. [Google Scholar] [CrossRef] [PubMed]
- Liriano, F.; Hatten, C.; Schwartz, T.L. Ketamine as Treatment for Post-Traumatic Stress Disorder: A Review. Drugs Context 2019, 8, 212305. [Google Scholar] [CrossRef] [Green Version]
- Asim, M.; Wang, B.; Hao, B.; Wang, X. Ketamine for Post-Traumatic Stress Disorders and It’s Possible Therapeutic Mechanism. Neurochem. Int. 2021, 146, 105044. [Google Scholar] [CrossRef] [PubMed]
- Strong, C.E.; Kabbaj, M. Neural Mechanisms Underlying the Rewarding and Therapeutic Effects of Ketamine as a Treatment for Alcohol Use Disorder. Front. Behav. Neurosci. 2020, 14, 593860. [Google Scholar] [CrossRef]
- Chang, C.-H.; Lane, H.-Y.; Tseng, P.-T.; Chen, S.-J.; Liu, C.-Y.; Lin, C.-H. Effect of N-Methyl-D-Aspartate-Receptor-Enhancing Agents on Cognition in Patients with Schizophrenia: A Systematic Review and Meta-Analysis of Double-Blind Randomised Controlled Trials. J. Psychopharmacol. 2019, 33, 436–448. [Google Scholar] [CrossRef] [PubMed]
- Stippl, A.; Scheidegger, M.; Aust, S.; Herrera, A.; Bajbouj, M.; Gärtner, M.; Grimm, S. Ketamine Specifically Reduces Cognitive Symptoms in Depressed Patients: An Investigation of Associated Neural Activation Patterns. J. Psychiatr. Res. 2021, 136, 402–408. [Google Scholar] [CrossRef] [PubMed]
- Mills, I.H.; Park, G.R.; Manara, A.R.; Merriman, R.J. Treatment of Compulsive Behaviour in Eating Disorders with Intermittent Ketamine Infusions. QJM Mon. J. Assoc. Physicians 1998, 91, 493–503. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Schwartz, T.; Trunko, M.E.; Feifel, D.; Lopez, E.; Peterson, D.; Frank, G.K.W.; Kaye, W. A Longitudinal Case Series of IM Ketamine for Patients with Severe and Enduring Eating Disorders and Comorbid Treatment-Resistant Depression. Clin. Case Rep. 2021, 9, e03869. [Google Scholar] [CrossRef]
- Scolnick, B.; Zupec-Kania, B.; Calabrese, L.; Aoki, C.; Hildebrandt, T. Remission from Chronic Anorexia Nervosa With Ketogenic Diet and Ketamine: Case Report. Front. Psychiatry 2020, 11, 763. [Google Scholar] [CrossRef] [PubMed]
- Dechant, E.; Boyle, B.; Ross, R.A. Ketamine in a Patient with Comorbid Anorexia and MDD. J. Women’s Health Dev. 2020, 3, 373–375. [Google Scholar] [CrossRef]
- Ragnhildstveit, A.; Jackson, L.K.; Cunningham, S.; Good, L.; Tanner, Q.; Roughan, M.; Henrie-Barrus, P. Case Report: Unexpected Remission From Extreme and Enduring Bulimia Nervosa With Repeated Ketamine Assisted Psychotherapy. Front. Psychiatry 2021, 12, 764112. [Google Scholar] [CrossRef]
- Walsh, Z.; Mollaahmetoglu, O.M.; Rootman, J.; Golsof, S.; Keeler, J.; Marsh, B.; Nutt, D.J.; Morgan, C.J.A. Ketamine for the Treatment of Mental Health and Substance Use Disorders: Comprehensive Systematic Review. BJPsych Open 2021, 8, e19. [Google Scholar] [CrossRef] [PubMed]
- Ito, Y.; Ichiyanagi, K. Post-Operative Pain Relief with Ketamine Infusion. Anaesthesia 1974, 29, 222–226. [Google Scholar] [CrossRef]
- Bion, J.F. Infusion Analgesia for Acute War Injuries. A Comparison of Pentazocine and Ketamine. Anaesthesia 1984, 39, 560–564. [Google Scholar] [CrossRef] [PubMed]
- Holman, R.T.; Adams, C.E.; Nelson, R.A.; Grater, S.J.; Jaskiewicz, J.A.; Johnson, S.B.; Erdman, J.W. Patients with Anorexia Nervosa Demonstrate Deficiencies of Selected Essential Fatty Acids, Compensatory Changes in Nonessential Fatty Acids and Decreased Fluidity of Plasma Lipids. J. Nutr. 1995, 125, 901–907. [Google Scholar] [CrossRef]
- Shih, P.B.; Yang, J.; Morisseau, C.; German, J.B.; Zeeland, A.A.S.-V.; Armando, A.M.; Quehenberger, O.; Bergen, A.W.; Magistretti, P.; Berrettini, W.; et al. Dysregulation of Soluble Epoxide Hydrolase and Lipidomic Profiles in Anorexia Nervosa. Mol. Psychiatry 2016, 21, 537–546. [Google Scholar] [CrossRef] [Green Version]
- Watson, H.J.; Yilmaz, Z.; Thornton, L.M.; Hübel, C.; Coleman, J.R.I.; Gaspar, H.A.; Bryois, J.; Hinney, A.; Leppä, V.M.; Mattheisen, M.; et al. Genome-Wide Association Study Identifies Eight Risk Loci and Implicates Metabo-Psychiatric Origins for Anorexia Nervosa. Nat. Genet. 2019, 51, 1207–1214. [Google Scholar] [CrossRef] [Green Version]
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-5TM, 5th ed.; American Psychiatric Publishing, Inc.: Arlington, VA, USA, 2013; p. xliv, 947. ISBN 978-0-89042-554-1. [Google Scholar]
- Newport, D.J.; Carpenter, L.L.; McDonald, W.M.; Potash, J.B.; Tohen, M.; Nemeroff, C.B.; APA Council of Research Task Force on Novel Biomarkers and Treatments. Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression. Am. J. Psychiatry 2015, 172, 950–966. [Google Scholar] [CrossRef] [Green Version]
- Kishimoto, T.; Chawla, J.M.; Hagi, K.; Zarate, C.A.; Kane, J.M.; Bauer, M.; Correll, C.U. Single-Dose Infusion Ketamine and Non-Ketamine N-Methyl-d-Aspartate Receptor Antagonists for Unipolar and Bipolar Depression: A Meta-Analysis of Efficacy, Safety and Time Trajectories. Psychol. Med. 2016, 46, 1459–1472. [Google Scholar] [CrossRef] [Green Version]
- Harding, F.; Seynaeve, M.; Keeler, J.; Himmerich, H.; Treasure, J.; Kan, C. Perspectives on Psychedelic Treatment and Research in Eating Disorders: A Web-Based Questionnaire Study of People with Eating Disorders. J. Integr. Neurosci. 2021, 20, 551–560. [Google Scholar] [CrossRef]
- Renelli, M.; Fletcher, J.; Tupper, K.W.; Files, N.; Loizaga-Velder, A.; Lafrance, A. An Exploratory Study of Experiences with Conventional Eating Disorder Treatment and Ceremonial Ayahuasca for the Healing of Eating Disorders. Eat. Weight Disord.—Stud. Anorex. Bulim. Obes. 2020, 25, 437–444. [Google Scholar] [CrossRef]
- Brewerton, T.D.; Wang, J.B.; Lafrance, A.; Pamplin, C.; Mithoefer, M.; Yazar-Klosinki, B.; Emerson, A.; Doblin, R. MDMA-Assisted Therapy Significantly Reduces Eating Disorder Symptoms in a Randomized Placebo-Controlled Trial of Adults with Severe PTSD. J. Psychiatr. Res. 2022, 148, 128–135. [Google Scholar] [CrossRef]
- Spriggs, M.J.; Kettner, H.; Carhart-Harris, R.L. Positive Effects of Psychedelics on Depression and Wellbeing Scores in Individuals Reporting an Eating Disorder. Eat. Weight Disord. EWD 2021, 26, 1265–1270. [Google Scholar] [CrossRef]
- Spriggs, M.J.; Douglass, H.M.; Park, R.J.; Read, T.; Danby, J.L.; de Magalhães, F.J.C.; Alderton, K.L.; Williams, T.M.; Blemings, A.; Lafrance, A.; et al. Study Protocol for “Psilocybin as a Treatment for Anorexia Nervosa: A Pilot Study”. Front. Psychiatry 2021, 12, 735523. [Google Scholar] [CrossRef]
- Ernst, J.; Böker, H.; Hättenschwiler, J.; Schüpbach, D.; Northoff, G.; Seifritz, E.; Grimm, S. The Association of Interoceptive Awareness and Alexithymia with Neurotransmitter Concentrations in Insula and Anterior Cingulate. Soc. Cogn. Affect. Neurosci. 2014, 9, 857–863. [Google Scholar] [CrossRef] [Green Version]
- Nakazato, M.; Hashimoto, K.; Schmidt, U.; Tchanturia, K.; Campbell, I.C.; Collier, D.A.; Iyo, M.; Treasure, J. Serum Glutamine, Set-Shifting Ability and Anorexia Nervosa. Ann. Gen. Psychiatry 2010, 9, 29. [Google Scholar] [CrossRef] [Green Version]
- Sleigh, J.; Harvey, M.; Voss, L.; Denny, B. Ketamine—More Mechanisms of Action than Just NMDA Blockade. Trends Anaesth. Crit. Care 2014, 4, 76–81. [Google Scholar] [CrossRef] [Green Version]
- Strasburger, S.E.; Bhimani, P.M.; Kaabe, J.H.; Krysiak, J.T.; Nanchanatt, D.L.; Nguyen, T.N.; Pough, K.A.; Prince, T.A.; Ramsey, N.S.; Savsani, K.H.; et al. What Is the Mechanism of Ketamine’s Rapid-Onset Antidepressant Effect? A Concise Overview of the Surprisingly Large Number of Possibilities. J. Clin. Pharm. Ther. 2017, 42, 147–154. [Google Scholar] [CrossRef]
- Wilkinson, S.T.; Ballard, E.D.; Bloch, M.H.; Mathew, S.J.; Murrough, J.W.; Feder, A.; Sos, P.; Wang, G.; Zarate, C.A.; Sanacora, G. The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis. Am. J. Psychiatry 2018, 175, 150–158. [Google Scholar] [CrossRef] [PubMed]
- Krystal, J.H.; Abdallah, C.G.; Sanacora, G.; Charney, D.S.; Duman, R.S. Ketamine: A Paradigm Shift for Depression Research and Treatment. Neuron 2019, 101, 774–778. [Google Scholar] [CrossRef] [Green Version]
- McMullen, E.P.; Lee, Y.; Lipsitz, O.; Lui, L.M.W.; Vinberg, M.; Ho, R.; Rodrigues, N.B.; Rosenblat, J.D.; Cao, B.; Gill, H.; et al. Strategies to Prolong Ketamine’s Efficacy in Adults with Treatment-Resistant Depression. Adv. Ther. 2021, 38, 2795–2820. [Google Scholar] [CrossRef]
- Aroke, E.N.; Crawford, S.L.; Dungan, J.R. Pharmacogenetics of Ketamine-Induced Emergence Phenomena: A Pilot Study. Nurs. Res. 2017, 66, 105–114. [Google Scholar] [CrossRef] [Green Version]
- Hasler, G. Toward Specific Ways to Combine Ketamine and Psychotherapy in Treating Depression. CNS Spectr. 2020, 25, 445–447. [Google Scholar] [CrossRef] [Green Version]
- Dore, J.; Turnipseed, B.; Dwyer, S.; Turnipseed, A.; Andries, J.; Ascani, G.; Monnette, C.; Huidekoper, A.; Strauss, N.; Wolfson, P. Ketamine Assisted Psychotherapy (KAP): Patient Demographics, Clinical Data and Outcomes in Three Large Practices Administering Ketamine with Psychotherapy. J. Psychoact. Drugs 2019, 51, 189–198. [Google Scholar] [CrossRef] [Green Version]
- Wilkinson, S.T.; Wright, D.; Fasula, M.K.; Fenton, L.; Griepp, M.; Ostroff, R.B.; Sanacora, G. Cognitive Behavior Therapy May Sustain Antidepressant Effects of Intravenous Ketamine in Treatment-Resistant Depression. Psychother. Psychosom. 2017, 86, 162–167. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Krupitsky, E.M.; Burakov, A.M.; Romanova, T.N.; Dunaevsky, I.V.; Grinenko, A.Y. Ketamine Assisted Psychotherapy (KPT) of Heroin Addiction: Immediate Effects and Six Months Followup. MAPS Bull. 2001, 9, 21–26. [Google Scholar]
- Halstead, M.; Reed, S.; Krause, R.; Williams, M.T. Ketamine-Assisted Psychotherapy for PTSD Related to Racial Discrimination. Clin. Case Stud. 2021, 20, 310–330. [Google Scholar] [CrossRef]
- Davis, A.K.; Mangini, P.; Xin, Y. Ketamine-Assisted Psychotherapy for Trauma-Exposed Patients in an Outpatient Setting: A Clinical Chart Review Study. J. Psychedelic Stud. 2021, 5, 94–102. [Google Scholar] [CrossRef]
Study [Ref] | Design | Sample, Age/Mean Age | Diagnosis | Drug Regimen | Outcome |
---|---|---|---|---|---|
Dechant et al. [139] | Case study | N = 1, 29 | AN-R + MDD | IV ketamine, 9 × 0.5 mg/kg over 40 min | Partial remission: depression and suicidality |
Mills et al. [136] | Case series | N = 15, 33.3 years ± 6.5 | AN-R, AN-BP | IV ketamine, 2–15 × 20 mg/h over 10 h | Partial remission: depression and OCD-related ED symptoms |
Ragnhildstveit et al. [140] | Case study | N = 1, 21 | BN-BP | IV ketamine, 18 × 0.5 mg/kg over 40 min | Complete and sustained remission: ED symptoms |
Schwartz et al. [137] | Case series | N = 4, 36.8 years ± 8.4 | AN-R + TRD, EDNOS-BP + TRD | IV/IM ketamine, 5–9 × 0.5 mg/kg titrated to 0.9 mg/kg over 30–90 min | Partial remission: depression, anxiety, and ED symptoms |
Scolnick et al. [138] | Case study | N = 1, 29 | AN-R + MDD | IV ketamine, 4 × 0.75 mg/kg titrated to 1.2 mg/kg over 45 min | Complete and sustained remission: depression and OCD-related ED symptoms |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Ragnhildstveit, A.; Slayton, M.; Jackson, L.K.; Brendle, M.; Ahuja, S.; Holle, W.; Moore, C.; Sollars, K.; Seli, P.; Robison, R. Ketamine as a Novel Psychopharmacotherapy for Eating Disorders: Evidence and Future Directions. Brain Sci. 2022, 12, 382. https://doi.org/10.3390/brainsci12030382
Ragnhildstveit A, Slayton M, Jackson LK, Brendle M, Ahuja S, Holle W, Moore C, Sollars K, Seli P, Robison R. Ketamine as a Novel Psychopharmacotherapy for Eating Disorders: Evidence and Future Directions. Brain Sciences. 2022; 12(3):382. https://doi.org/10.3390/brainsci12030382
Chicago/Turabian StyleRagnhildstveit, Anya, Matthew Slayton, Laura Kate Jackson, Madeline Brendle, Sachin Ahuja, Willis Holle, Claire Moore, Kellie Sollars, Paul Seli, and Reid Robison. 2022. "Ketamine as a Novel Psychopharmacotherapy for Eating Disorders: Evidence and Future Directions" Brain Sciences 12, no. 3: 382. https://doi.org/10.3390/brainsci12030382